rupiya.io
⠋Loading...
0%
❯ Aggregating market cap data...
Aarti Pharmalabs Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Aarti Pharmalabs Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | ₹1,200 Cr | ₹1,945 Cr | ₹1,853 Cr | |
| Expenses | ₹993 Cr | ₹1,603 Cr | ₹1,467 Cr | |
| Operating Profit | ₹207 Cr | ₹342 Cr | ₹386 Cr | |
| OPM % | 17.0% | 18.0% | 21.0% | |
| Other Income | ₹3 Cr | ₹2 Cr | ₹5 Cr | |
| Depreciation | ₹42 Cr | ₹63 Cr | ₹73 Cr | |
| Interest | ₹12 Cr | ₹21 Cr | ₹17 Cr | |
| Profit Before Tax | ₹155 Cr | ₹261 Cr | ₹300 Cr | |
| Tax | ₹155 Cr | ₹261 Cr | ₹300 Cr | |
| Net Profit | ₹122 Cr | ₹193 Cr | ₹217 Cr | |
| EPS (₹) | 0.0 | 21.4 | 23.9 | |
| Dividend Payout % | 0% | 9% | 13% |
Register free to see 1 more year.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹472 Cr | ₹485 Cr | ₹458 Cr | ₹440 Cr | ||||||||
| Expenses | ₹385 Cr | ₹405 Cr | ₹373 Cr | ₹352 Cr | ||||||||
| Operating Profit | ₹86 Cr | ₹80 Cr | ₹85 Cr | ₹88 Cr | ||||||||
| OPM % | 18.0% | 16.0% | 19.0% | 20.0% | ||||||||
| Depreciation | ₹16 Cr | ₹16 Cr | ₹17 Cr | ₹18 Cr | ||||||||
| Interest | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹4 Cr | ||||||||
| Net Profit | ₹48 Cr | ₹43 Cr | ₹47 Cr | ₹52 Cr | ||||||||
| EPS (₹) | 5.3 | 4.7 | 5.2 | 5.7 |
Register free to see 8 more quarters.
| Period | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹0 Cr | ₹0 Cr | ₹45 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹0 Cr | ₹1,386 Cr | ₹1,513 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹0 Cr | ₹341 Cr | ₹215 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹0 Cr | ₹312 Cr | ₹470 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹0 Cr | ₹2,040 Cr | ₹2,244 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹0 Cr | ₹782 Cr | ₹926 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹32 Cr | ₹87 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹0 Cr | ₹1,038 Cr | ₹1,130 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹0 Cr | ₹2,040 Cr | ₹2,244 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 1 more year.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2023 | ₹-44 Cr | ₹-139 Cr | ₹260 Cr | — |
| Mar 2024 | ₹250 Cr | ₹-158 Cr | ₹-163 Cr | — |
| Mar 2025 | ₹216 Cr | ₹-215 Cr | ₹10 Cr | — |
Register free to see 1 more year.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +8.45% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.74% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -5.78% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +7.74% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +3.69% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.